Search Results for "donepezil"
Search again or select article below to purchase. Single article price: $45. Order 3 or more at one time and receive a 10% discount.
Sort by relevance | Sort by date
Searched for donepezil. Results 11 to 15 of 15 total matches.
See also: Aricept
Donanemab (Kisunla) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Aug 19, 2024 (Issue 1709)
— The acetylcholinesterase
inhibitors donepezil, rivastigmine, and galantamine
and the NMDA-receptor antagonist memantine ...
Donanemab-azbt (Kisunla – Lilly), an IV amyloid beta-directed
monoclonal antibody, has been approved by
the FDA for treatment of Alzheimer's disease (AD).
The label states that the drug should only be started
in patients with mild cognitive impairment (MCI) or
mild dementia. Donanemab is the third IV amyloid
beta-directed monoclonal antibody to be marketed
in the US. Lecanemab (Leqembi – Biogen/Eisai) was
approved by the FDA in 2023 for the same indication
as donanemab. Aducanumab (Aduhelm – Lilly)
was granted accelerated approval in 2021, but it
was withdrawn from the market...
Med Lett Drugs Ther. 2024 Aug 19;66(1709):129-31 doi:10.58347/tml.2024.1709a | Show Introduction Hide Introduction
A Rivastigmine Patch for Dementia
The Medical Letter on Drugs and Therapeutics • Mar 24, 2008 (Issue 1282)
Donepezil – Aricept (Esai/Pfizer) 5 or 10 mg tabs 5-10 mg once 5 mg once/d; after 4-6 wks $181.50
Aricept ...
Cholinesterase inhibitors are now used routinely in patients with dementia. Rivastigmine transdermal system (Exelon Patch - Novartis), a patch formulation of the cholinesterase inhibitor rivastigmine tartrate, has been approved by the FDA for treatment of mild to moderate dementia associated with Alzheimer's or Parkinson's disease. An oral formulation of rivastigmine tartrate has been available in the US since 2000,2 but gastrointestinal adverse effects possibly related to rapidly rising serum concentrations have limited its use.
Solifenacin and Darifenacin for Overactive Bladder
The Medical Letter on Drugs and Therapeutics • Mar 14, 2005 (Issue 1204)
such as donepezil (Aricept) used to treat
Alzheimer’s disease and anticholinergic drugs may
interfere with each ...
Solifenacin succinate (VESIcare - Yamanouchi and GlaxoSmithKline) and darifenacin hydrobromide (Enablex - Novartis) have been approved by the FDA for oral treatment of overactive bladder.
Lecanemab (Leqembi) for Alzheimer's Disease
The Medical Letter on Drugs and Therapeutics • Feb 06, 2023 (Issue 1669)
— The acetylcholinesterase
inhibitors donepezil, rivastigmine, and galantamine,
the NMDA-receptor antagonist memantine ...
Lecanemab-irmb (Leqembi – Biogen/Eisai), an IV
amyloid beta-directed monoclonal antibody, has
received accelerated approval from the FDA for
treatment of Alzheimer's disease. The label states
that treatment with Leqembi should be initiated in
patients with mild cognitive impairment (MCI) or
mild dementia, the population in which the drug was
initiated in clinical trials. Lecanemab is the second
IV amyloid-beta directed monoclonal antibody to be
approved for this indication; aducanumab (Aduhelm)
was approved in 2021 and has the same restrictions
on treatment...
Med Lett Drugs Ther. 2023 Feb 6;65(1669):17-8 doi:10.58347/tml.2023.1669a | Show Introduction Hide Introduction
Drugs for Parkinson's Disease
The Medical Letter on Drugs and Therapeutics • Feb 22, 2021 (Issue 1618)
OF DEMENTIA — The oral acetylcholinesterase
inhibitors donepezil (Aricept, and
generics), rivastigmine ...
The motor symptoms of Parkinson's disease (PD) are
caused primarily by degeneration of dopaminergic
neurons in the substantia nigra. The nonmotor symptoms
of the disease are thought to be caused by degeneration of
other neurotransmitter systems. No disease-modifying
drugs are available for treatment of PD.